Sarepta Therapeutics (SRPT) Says USPTO Issued Favorable Decisions on Exon 51 and Exon 53 Composition in Case vs BioMarin (BMRN)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/23/2024
- Stocks gear up for Big Tech earnings; yen toys with danger zone
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises on robust EU data as Mideast tensions linger
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- SAP Q1 results fall short of Wall Street estimates as transformation kicks off
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
BioMarin Pharma (BMRN) Will Seek Review of PTAB Exon 51 Composition of Matter Patent Decision (SRPT)
September 21, 2016 8:55 AM EDTBioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that it intends to seek a review of the Patent Trial and Appeal Board (PTAB) of the United States ruling in Interference No. 106,008, related to composition of matter (COM) claims related to exon 51 skipping antisense oligonucleotides. BioMarin is completing its review of the decision and the specific means it may use to seek a further review.
BioMarin also notes that on September 29, 2015, the PTAB ruled in BioMarins favor in Interference No. 106,013 directed to the method of use (MOU) of exon 51 skipping antisense oligonucleotides to treat Duchenne muscular... More
Baird Affirms Sarepta Therapeutics (SRPT) at 'Outperform'; Incrementally Positive on PTAB Decision (BMRN)
September 21, 2016 6:26 AM EDTBaird is incrementally positive on the PTAB ruling for Sarepta Therapeutics, Inc. (NASDAQ: SRPT), which was announced late Tuesday.
Analyst Brian Skorney commented today, Though the dominant story last year was the battle for approval between eteplirsen and BioMarin's (Nasdaq:... More
